RegenCen Review

What RegenCen charges

RegenCen does not publish a price today.

RegenCen also sells 5 compounds this site boards without publishing a price for them: NAD+, Sermorelin, Ipamorelin (board ranks no provider), BPC-157 (board ranks no provider) and GHK-Cu.

It takes a public position on research-use sellers

On its peptide-therapy page, RegenCen argues that compounds sold for research purposes only are simply unproven, and says others have been explicitly prohibited from human use by the FDA.

That is RegenCen's own claim, in RegenCen's own words, and the page attaches no source to it. Nothing on this site restates it as fact or endorses it.

The value to a reader is that the clinic commits to a sourcing position in public. Most sellers in this category stay silent, which leaves a buyer nothing to hold them to later.

The operator is hidden in plain sight

The about page names a management company whose name shares no words with the brand. A reader would never guess it, and nothing on the page explains the relationship.

It is still a disclosure, and a better one than the silence common across this roster. The company is published; it is simply published under a name nobody would search for.

Anyone checking licenses, filings or complaints should run the management-company name rather than the brand, or the search will come back empty for the wrong reason.

Five compounds and no figures

RegenCen names NAD+, sermorelin, ipamorelin, BPC-157 and GHK-Cu across its treatment pages, and runs peptide therapy as its own page rather than a footnote to the IV line.

None of the six pages read carries a figure for any of those five. Cost is settled after contact, in a consult, and the site gives no range to anchor against.

A shopper comparing sellers on price will get nothing usable here. The material this clinic publishes is about approach and sourcing, not about money.

What is left to the consult

No list of states appears on the site. Eligibility is therefore decided during intake rather than checked by the reader beforehand.

The facility that compounds or dispenses is not named anywhere. A buyer has no pharmacy to look up before agreeing to a course.

No lab work is described as included in what the clinic charges. Assume any panel is billed separately and confirm that in the consult.

How we verified this

• Read the peptide-therapy page and recorded the regulatory claim as the clinic's own wording, attributed rather than adopted.
• Checked the same page for a citation behind that claim and recorded that the assertion stands on its own.
• Read the about page for the operating company and recorded the name exactly as printed, noting it shares nothing with the brand.
• Checked six pages for any figure attached to NAD+, sermorelin, ipamorelin, BPC-157 or GHK-Cu, and recorded that none carries one.
• Screened this clinic against the federal warning-letter record by company name and by brand, with a known-positive and a nonsense control run alongside it.